Replies to post #243373 on Avid Bioservices Inc (CDMO)

[biopharm]

That is pure genius

thanks bluerinse, although I know you don't mean literally a genius, and speaking of a genius...

I'd have to place the late Dr. Philip Thorpe in that category and being able to put puzzle pieces together is one thing, but Dr. Thorpe spent his life researching and he decided to move forward with PS Targeting. Maybe we will all find out soon enough how that decision and chain of events plays out...

There were a dozen major clues along the way, one being the decision made by MD Anderson to license out "Clipped B2GP1" to Peregrine Pharmaceuticals and why ? Maybe during those days it was known how valuable PS Targeting would become and I don't like to ask all the tough questions time and time again...

... but the sabotage against Peregrine, if it ever resulted in the bankruptcy of PPHM ( probably closer than some of us know...), then would have those in early, close collaborations with MD Anderson benefited from some company picking up Peregrine for breadcrumbs ?? Lots of questions... but hey, at least Dr. James Allison should realize that when even Dr. Jedd Wolchok steps up to bat (even if it was a foul ball and he'll be given plenty more chances to place PPHM in the spotlight again...), then maybe its time for even Dr. James Allison to realize things are changing...

This is just a small clip below from CJ's post back in 2007 and how time flies. I bet some Big Pharma wish they had taken a much different approach back during these days, after seeing how it all turned out and seeing Peregrine is a couple PR's away from all hell breaking loose in Big Pharma. Maybe Pfizer is another tremor in the background of that hell breaking loose...

PR 7-9-07: Peregrine Licenses MDA’s “Clipped B2GP1” (invented by MDA’s Dr. Alan Schroit, PPHM SRB member – this is the basis for PS-targeting “BetaBodies” – ie, 2nd-gen. Bavi)…

…Dr. Schroit: “Clipped forms of B2GP1 may represent an exciting new approach for anti-angiogenesis therapies, and I am pleased to be collaborating with Peregrine to further explore its clinical utility. The more we learn about this plasma protein, the more intriguing its role appears to be. The anti-angiogenic potential of B2GP1 was first identified by my lab in studies suggesting that it is a negative regulator of angiogenesis that can inhibit the growth of primary tumors and metastases. 1st-Gen. anti-angiogenesis agents have already demonstrated their value in some cancer and ophthalmology applications, and we are eager to learn more about the clinical potential of this new anti-angiogenesis approach."

“Peregrine Acquires Worldwide (Exclusive) Rights to Novel Anti-Angiogenesis Technology From M. D. Anderson Cancer Center”

• “all forms of ‘clipped’ (or nicked) Beta 2 Glycoprotein 1 (B2GP1) protein”
investorshub.advfn.com/boards/read_msg.aspx?message_id=21055309
Correct PR link: http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=266033

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=89680206

Now back to cutting grass and landscaping... something I will surely accept at being a genius in... where the grass is always green : )